Oguma S, Tatsumi Y, Hirayama F, Tani Y, Kubota Y, Kanakura Y, Ueda T, Nakamura H, Shibata H, Masaoka T
Gan To Kagaku Ryoho. 1984 Mar;11(3):497-501.
A total of seventeen patients with acute leukemia were treated with mitoxantrone for induction therapy. Nine out of 17 patients were previously untreated, while the other eight patients were previously treated. All of the previously treated cases had received chemotherapy including anthracycline derivatives. Bolus infusion of Mitoxantrone for three to ten days was employed. The daily and total doses of mitoxantrone ranged from 1.8 mg/m2 to 4.3 mg/m2 and from 7.5 mg/m2 to 40 mg/m2, respectively. CR was achieved in three (33%) previously untreated and two (25%) in previously treated cases. PR occurred in five previously untreated and in two previously treated patients. The other five failed to respond the agent. The most serious adverse effect of the drug was myelosuppression, but it was reversible in all cases. In one patient irreversible EKG change was observed. All other adverse effects such as nausea and vomiting, anorexia and diarrhea, were not serious and reversible. In conclusion, Mitoxantrone is effective in some cases with acute leukemia.
共有17例急性白血病患者接受米托蒽醌诱导治疗。17例患者中有9例此前未接受过治疗，另外8例患者此前接受过治疗。所有此前接受过治疗的病例均接受过包括蒽环类衍生物在内的化疗。采用米托蒽醌静脉推注3至10天。米托蒽醌的每日剂量和总剂量分别为1.8mg/m²至4.3mg/m²和7.5mg/m²至40mg/m²。3例（33%）此前未接受过治疗的患者和2例（25%）此前接受过治疗的患者达到完全缓解（CR）。5例此前未接受过治疗的患者和2例此前接受过治疗的患者出现部分缓解（PR）。另外5例患者对该药物无反应。该药物最严重的不良反应是骨髓抑制，但在所有病例中均可逆转。1例患者观察到不可逆的心电图改变。所有其他不良反应，如恶心、呕吐、厌食和腹泻，均不严重且可逆转。总之，米托蒽醌对某些急性白血病病例有效。
